OVARIAN CANCER SCREENING STUDY

卵巢癌筛查研究

• 批准号: 7376468
• 负责人: SAUNDRA S BUYS
• 金额: $ 5.27万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376468
• 关键词: ovary neoplasms

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Women with mutations in specific cancer predisposition genes have an increased risk for developing ovarian cancer. This risk may be as high as 60% in some families. Ovarian cancer is difficult to detect early, and most women present at an advanced stage at which time cure is unlikely. CA125 is a protein that is often elevated in women with ovarian cancer and is being evaluated as a means of early detection of ovarian cancer. Since ovarian cancer may go from undetectable to incurable relatively rapidly, annual measurements of CA125 may miss many cases of curable ovarian cancer. This study is a multi-institutional pilot trial sponsored by the Cancer Genetics Network. Utah is one of six sites in the network. We will screen high-risk women for ovarian cancer with CA125 at three-month intervals. Baseline CA125 values, a priori risk of ovarian cancer based on age and family history, and change in CA125 values with time are used to calculate the risk of ovarian cancer. If the study design and preliminary outcomes appear feasible and promising, the study will be expanded to allow for definitive assessment of efficacy of screening.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。具有特定癌症易感基因突变的女性患卵巢癌的风险增加。在某些家庭中，这种风险可能高达60%。卵巢癌很难早期发现，大多数妇女都处于晚期，此时治愈是不可能的。CA 125是一种在卵巢癌患者中经常升高的蛋白质，目前正在评估其作为卵巢癌早期检测的一种手段。由于卵巢癌可能会从无法检测到无法治愈相对较快，CA 125的年度测量可能会错过许多可治愈的卵巢癌病例。这项研究是由癌症遗传学网络赞助的多机构试点试验。犹他州是该网络的六个站点之一。我们将每隔三个月用CA 125对卵巢癌高危妇女进行筛查。基线CA 125值，基于年龄和家族史的卵巢癌先验风险，以及CA 125值随时间的变化用于计算卵巢癌的风险。如果研究设计和初步结局可行且有前景，则将扩展研究，以明确评估筛选的疗效。